PMV Pharmaceuticals, Inc. (PMVP)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know
PMV Pharmaceuticals gains on promising rezatapopt data in ovarian cancer, FDA support for accelerated approval and a planned 2027 NDA filing.
PMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer Opportunity
PMV Pharmaceuticals is rated Buy, targeting $3–$4/share, driven by rezatapopt's 46% response rate and 10-month median duration in Y220C-mutant ovarian cancer. PMVP's medicinal chemistry leverages the Y220C mutation to stabilize p53, translating into consistent clinical activity across heavily pretreated patients. Risks include a limited initial market, acquired resistance, significant dilution from recent financings, and pivotal Phase 2 data due in Q4 2026.
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?
PMV Pharmaceuticals, Inc. (PMVP) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PMVP's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
PMV Pharmaceuticals, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| KT Kevin Tang Tang Capital Management LLC | 4.25M | $5.92M | $5.26M | -$655,993.34 | -11.08% |
| AWM Accurate Wealth Management LLC Accurate Wealth Management LLC | 50,000 | $62,000 | $63,000 | $1,000 | 1.61% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 18 | $23.72 | $23.22 | -$0.5 | -2.11% |
| RJ Rebecca Judd Pathstone Holdings, LLC | 17,487 | $18,536 | $22,558.23 | $4,022.23 | 21.7% |
| BCG BIT Capital GmbH BIT Capital GmbH | 407,555 | $533,768.2 | $531,859.27 | -$1,908.93 | -0.36% |
PMV Pharmaceuticals, Inc. (PMVP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has PMV Pharmaceuticals, Inc. ever had a stock split?
PMV Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | David H. Mack CEO | NASDAQ (NGS) Exchange | 69353Y103 CUSIP |
| US Country | 54 Employees | - Last Dividend | - Last Split | 25 Sep 2020 IPO Date |
Overview
PMV Pharmaceuticals, Inc. is a precision oncology company engaged in the groundbreaking field of developing therapeutic solutions targeted at specific mutations responsible for cancer. The focal point of their research and development efforts lies in tackling mutations of the p53 gene, which plays a crucial role in preventing cancer formation, thereby acting as a tumor suppressor. Founded initially as PJ Pharmaceuticals, Inc., the company underwent a rebranding to PMV Pharmaceuticals, Inc. in July 2013, marking the beginning of a dedicated pursuit towards leveraging precision medicine to battle the most challenging cancers. Headquartered in Princeton, New Jersey, and established in 2013, PMV Pharmaceuticals has quickly positioned itself as a prominent player in the quest for innovative cancer treatments.
Products and Services
- PC14586
Contact Information
